TY - JOUR T1 - A Probabilistic Approach to Physician-Assisted Suicide JF - medRxiv DO - 10.1101/2023.01.24.23284910 SP - 2023.01.24.23284910 AU - Oded Nov Y1 - 2023/01/01 UR - http://medrxiv.org/content/early/2023/01/25/2023.01.24.23284910.abstract N2 - Physician-Assisted Suicide (PAS) is considered by some patients who learn they are at risk for a cognitive decline owing to Alzheimer’s Disease. At the same time, the prospect of PAS may raise patients’ fear of imminent death. Can PAS be offered in a way that is preference-sensitive on one hand, and mitigates patients’ fear of imminent death on the other? A thought experiment of a Probabilistic Approach to PAS (Probabilistic PAS) is proposed here as a possible solution in jurisdictions where PAS is legal.Consider the following scenario: A patient diagnosed with Alzheimer’s Disease who is considering PAS might request that when he or she can no longer recognize their loved ones, their doctor will give them a lethal pill that has a 1/100 daily probability of being activated. As a result, after taking the pill, every day the patient will have a 1/100 probability of dying. The likelihood of the patient dying within a year from taking the pill is 97.4%, and within two years, it is 99.9%. As such, a Probabilistic PAS with which on any given day the probability of dying is low, can help patients avoid the fear of imminent death – which traditional PAS entails – while respecting their preference to end their lives.To examine the potential reception of a Probabilistic PAS, a survey was administered to a nationally-representative sample of US residents, using Prolific, a research participant recruitment platform. 499 participants were presented with a short description of a patient who was diagnosed with Alzheimer’s Disease, is writing an advance directive and is considering ways to end their life painlessly when they can no longer recognize their loved ones. Participants were asked about their own preferences in case they were to face a similar situation, and whether helping administer Probabilistic PAS would be ethical for the patient’s provider.498 participants responded to the question about their own preference. 73.5% indicated that they would choose one of the two PAS options. Among those, 9.8% preferred a Probabilistic PAS over traditional PAS. Men were more likely than women to favor Probabilistic PAS for themselves. 482 participants indicated which option would be most ethical for the patient’s provider to administer. 48.1% indicated one of the two PAS options as most ethical. Among those, 10.3% considered Probabilistic PAS to be more ethical than traditional PAS. Men were more likely than women to consider the provider administering Probabilistic PAS to be most ethical.A version of the Probabilistic PAS proposed here should be considered as a preference-sensitive option presented by healthcare providers to patients considering advance care planning in places where PAS is available.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by NYU Institutional Review Board (IRB-FY2022-6529).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors ER -